Study in Patients With Relapsed/Refractory Primary Mediastinal Lymphoma Treated With Pembrolizumab or Nivolumab in Combination With Brentuximab Vedotin in a Real-life Context

Recruiting now

Conditions studied: Primary Mediastinal B Cell Lymphoma

In brief

Observational, Non-Interventional, Retrospective, Multicenter Study Focusing on the Efficacy and Safety of Pembrolizumab Monotherapy and Nivolumab in Combination With Brentuximab Vedotin in Clinical Practice Patients With Primary Mediastinal B Cell Lymphoma Relapsed/Refractory

Key facts

Study ID

NCT06781450

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

50

Starts

2022-04-23

Expected to finish

2025-12-01

Last updated by the study team

2025-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed diagnosis of Primary Mediastinal B Cell Lymphoma Relapsed/Refractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a real-life context with till Novembre 2021
• Age ≥ 18 years at enrollment
• Signature of written informed consent (where applicable)

You may not qualify if…

• Primary Mediastinal B Cell Lymphoma Relapsed/Refractory patients who underwent pembrolizumab as a single agent and nivolumab in combination with brentuximab vedotin in a clinical trial context.

Where it is running

• IRCCS Azienda Ospedaliero - Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)
• Azienda Ospedaliera Universitaria- POLICLINICO BARI — Bari, Italy (enrolling)
• Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.